The overwhelming reliance on targeting the two key pathological hallmarks of 70 AD in human clinical trials has been fueled in large part, by animal models that 71 faithfully replicate these pathologies and "respond" to experimental treatments 72 that clear them or prevent their development (7, 47) . Preclinical AD research 73 using transgenic mouse models has thus generated hundreds of publications, 74 many of them in high-impact, high-profile journals wherein a candidate 
ii.
A "lack of diversity" similarly afflicts human clinical research, albeit in another In our research, we have embraced the twin challenges of adopting diversity in Just as the concept of studying normal aging through serial assessments of cognitive and MRI data completed (37, 38, 53 iii) Global, untargeted proteomic profiling by LC-MS/MS and label free 414 quantification: These data were acquired in the MFG and precuneus regions.
415
(data acquired through collaboration with Nicholas Seyfried and Allan Levey,
416
Emory University and available at 417 https://www.synapse.org/#!Synapse:syn3606086).
419
In parallel analyses, we have also acquired targeted and global metabolomics data using 
